Phase 2 N01 Program
The Phase 2 N01 Program includes 9 contractors, most of whom consist of multi-institutional consortia, and includes a total of 27 NCI-designated Cancer Centers. These sites carry out early clinical trials with CTEP-held IND agents, with an emphasis on phase 2 trials, but including phase 1 trials as well.